Jamie Robyn

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Imatinib-responsive hypereosinophilia in a patient with B cell ALL
    Jamie Robyn
    Hematology Branch, National Heart Lung and Blood Institute National Institutes of Health Bethesda, MD 20892, USA
    Leuk Lymphoma 45:2497-501. 2004
  2. pmc Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Blood 110:3552-6. 2007
  3. ncbi request reprint Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome
    Amy D Klion
    Bldg 4, Rm 126, National Institutes of Health, Bethesda, MD 20892
    Blood 103:473-8. 2004
  4. ncbi request reprint Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome
    Jamie Robyn
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
    Br J Haematol 132:286-92. 2006
  5. ncbi request reprint KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities
    Irina Maric
    Department of Laboratory Medicine, Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Allergy Clin Immunol 120:680-7. 2007
  6. pmc Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis
    Todd M Wilson
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 20892 1881, USA
    Haematologica 96:459-63. 2011
  7. ncbi request reprint Treatment of systemic mastocytosis
    Todd M Wilson
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11C205, 10 Center Drive, MSC 1881, Bethesda, MD 20892, USA
    Immunol Allergy Clin North Am 26:549-73. 2006
  8. ncbi request reprint Imatinib-responsive hypereosinophilic syndrome
    Jamie Robyn
    Leuk Res 30:915-6. 2006
  9. doi request reprint Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion
    Idoya Lahortiga
    Human Genome Laboratory, Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium
    Haematologica 93:49-56. 2008

Detail Information

Publications9

  1. ncbi request reprint Imatinib-responsive hypereosinophilia in a patient with B cell ALL
    Jamie Robyn
    Hematology Branch, National Heart Lung and Blood Institute National Institutes of Health Bethesda, MD 20892, USA
    Leuk Lymphoma 45:2497-501. 2004
    ..He was subsequently diagnosed with CD10 positive precursor B lymphoblastic leukemia. This case underscores the importance of follow-up bone marrow examination in patients who demonstrate imatinib mesylate-responsive eosinophilia...
  2. pmc Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Blood 110:3552-6. 2007
    ..This trial was registered at http://www.clinicaltrials.gov as no. NCT00044304...
  3. ncbi request reprint Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome
    Amy D Klion
    Bldg 4, Rm 126, National Institutes of Health, Bethesda, MD 20892
    Blood 103:473-8. 2004
    ..The lack of reversal of cardiac abnormalities and persistence of the F/P mutation in some patients suggests that early intervention with higher doses of imatinib mesylate may be desirable in the treatment of patients with MHES...
  4. ncbi request reprint Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome
    Jamie Robyn
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
    Br J Haematol 132:286-92. 2006
    ..These results suggest that the mutation arises in a pluripotential haematopoietic progenitor cell capable of giving rise to multiple lineages. The basis for the preferential expansion of eosinophils and mast cells remains unclear...
  5. ncbi request reprint KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities
    Irina Maric
    Department of Laboratory Medicine, Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Allergy Clin Immunol 120:680-7. 2007
    ..It is of paramount importance, however, to distinguish between these 2 groups of patients because of differences in clinical sequelae, prognoses, and selection of treatment...
  6. pmc Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis
    Todd M Wilson
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 20892 1881, USA
    Haematologica 96:459-63. 2011
    ..Unlike other mature lineages, mast cell survival is dependent on KIT and the presence of these two activating mutations may have a greater impact on the expansion of this cell compartment and in resultant disease severity...
  7. ncbi request reprint Treatment of systemic mastocytosis
    Todd M Wilson
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11C205, 10 Center Drive, MSC 1881, Bethesda, MD 20892, USA
    Immunol Allergy Clin North Am 26:549-73. 2006
    ..This has directly translated into the development of novel targeted therapies. These therapies hold great promise to patients and health care providers that a "cure" for systemic mastocytosis may someday be obtainable...
  8. ncbi request reprint Imatinib-responsive hypereosinophilic syndrome
    Jamie Robyn
    Leuk Res 30:915-6. 2006
  9. doi request reprint Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion
    Idoya Lahortiga
    Human Genome Laboratory, Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium
    Haematologica 93:49-56. 2008
    ..We report an unusual case of a patient presenting with peripheral basophilia and systemic mastocytosis in whom cytogenetic analysis revealed a t(4;5)(q21.1;q31.3)...